Skip N2 Metastasis in Pulmonary Adenocarcinoma: Good Prognosis Similar to N1 Disease

被引:13
|
作者
Wang, Lin [1 ]
Ye, Guanzhi [1 ]
Xue, Liang [1 ]
Zhan, Cheng [1 ]
Gu, Jie [1 ]
Xi, Junjie [1 ]
Lin, Zongwu [1 ]
Jiang, Wei [1 ]
Ge, Di [1 ]
Wang, Qun [1 ]
机构
[1] Fudan Univ, Zhongshan Hosp, Dept Thorac Surg, 180 Fenglin Rd, Shanghai 200032, Peoples R China
关键词
Lymph node metastasis; N1; disease; N2; Pathological subtype; pN sub-classification; RESPIRATORY SOCIETY CLASSIFICATION; LYMPH-NODE INVOLVEMENT; LUNG ADENOCARCINOMA; INTERNATIONAL ASSOCIATION; IASLC/ATS/ERS CLASSIFICATION; CANCER; RECURRENCE; SURVIVAL; SUBTYPES; RESECTION;
D O I
10.1016/j.cllc.2020.02.027
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We analyzed the prognosis of lung adenocarcinoma to elucidate the influence of skip N2 metastasis. Skip N2 disease has a similar prognosis to N1 disease and is significantly better than that of non-skip N2 disease. Skip N2 has a prognostic advantage in patients with the acinar-predominant subtype. Pathological subtypes of lung adenocarcinoma may influence subgroup of patients with lymph node metastasis. Introduction: The prognostic effect and mechanism of skip N2 lung cancer remain unclear. Our study aimed to elucidate the influence of skip N2 on overall survival (OS) and disease-free survival (DFS) compared with N1 and non-skip N2 in patients with lung adenocarcinoma. Patients and Methods: Patients with lung adenocarcinoma and lymph node involvement between May 2011 and December 2015 were retrospectively analyzed. The outcomes of skip N2 patients were compared with N1 and non-skip N2 patients. Prognosis was further investigated according to the N status in different adenocarcinoma subtypes. Univariate and multivariate analyses were carried out to define independent risk factors for OS and DFS. Results: A total of 456 patients with lung adenocarcinoma, 169 with N1 disease, 81 with skip N2 disease, and 206 with non-skip N2 disease, were enrolled in this study. All tumors were invasive adenocarcinoma, and the predominant subtypes were acinar in 252, papillary in 42, solid in 119, micropapillary in 20, and invasive mucinous adenocarcinoma in 23 patients. The DFS and OS of N1 and skip N2 diseases were similar and significantly better than those of patients with non-skip N2 disease. The prognosis according to lymph node status was significantly different in acinar-predominant subtypes in terms of both OS and DFS. Conclusions: Skip N2 disease has a similar prognosis to N1 disease and is significantly better than that of non-skip N2 disease in relation to OS and DFS. Skip N2 has a prognostic advantage in patients with the acinar-predominant subtype. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:E423 / E434
页数:12
相关论文
共 50 条
  • [11] The postoperative prognosis of skip-N2 metastasis is favorable in small-cell lung carcinoma patients with pathological N2 classification: a propensity-score-adjusted retrospective multicenter study
    Wu, Lei-Lei
    Liang, Shen-Hua
    Jiang, Feng
    Qiu, Li-Hong
    Chen, Xiaolu
    Yu, Wan-Jun
    Li, Chong-Wu
    Qian, Jia-Yi
    Huang, Yang-Yu
    Lin, Peng
    Long, Hao
    Li, Zhi-Xin
    Li, Kun
    Ma, Guo-Wei
    Xie, Dong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [12] An Attempt to Polarize Human Neutrophils Toward N1 and N2 Phenotypes in vitro
    Ohms, Mareike
    Moeller, Sonja
    Laskay, Tamas
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [13] CT-based radiomics signature for the stratification of N2 disease risk in clinical stage I lung adenocarcinoma
    Yang, Minglei
    She, Yunlang
    Deng, Jiajun
    Wang, Tingting
    Ren, Yijiu
    Su, Hang
    Wu, Junqi
    Sun, Xiwen
    Jiang, Gening
    Fei, Ke
    Zhang, Lei
    Xie, Dong
    Chen, Chang
    TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 (06) : 876 - +
  • [14] The Impact of Skip vs. Non-Skip N2 Lymph Node Metastasis on the Prognosis of Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
    Wang, Xinxin
    Guo, Haixie
    Hu, Quanteng
    Ying, Yongquan
    Chen, Baofu
    FRONTIERS IN SURGERY, 2021, 8
  • [15] The association of visceral pleural invasion with skip N2 metastasis on clinical stage IA NSCLC
    Minamoto, Fabio
    Araujoa, Pedro
    D'Ambrosio, Paula
    Dela Vega, Alberto
    Lauricella, Leticia
    Pego-Fernandes, Paulo
    Terra, Ricardo
    CLINICS, 2024, 79
  • [16] Results of N1 and N2 surgery in non-small cell lung cancer
    Pfannschmidt, J.
    Kollmeier, J.
    CHIRURG, 2019, 90 (12): : 974 - 981
  • [17] Is there a role for upfront surgery in patients with N2 disease and good prognostic features?
    Lee, Candice
    Guel, David A.
    Weksler, Benny
    JOURNAL OF THORACIC DISEASE, 2019, 11 : S1199 - S1201
  • [18] What is Resectable N2 Disease, and What is Unresectable N2 Disease: A Surgeon's Viewpoint
    Kim, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1719 - S1719
  • [19] Slug and Vimentin downregulation at the metastatic site is associated with Skip-N2 metastasis of lung adenocarcinoma
    Saygideger, Yasemin
    Avci, Alper
    Bagir, Emine
    Demir, Burcu Saygideger
    Sezan, Aycan
    Ekici, Mucahit
    Baydar, Oya
    Erkin, Ozgur Cem
    DISCOVER ONCOLOGY, 2022, 13 (01)
  • [20] Skip metastasis in mediastinal lymph node is a favorable prognostic factor in N2 lung cancer patients: a meta-analysis
    Wang, Zihuai
    Cheng, Jiahan
    Huang, Wenyu
    Cheng, Diou
    Liu, Yilin
    Pu, Qiang
    Reticker-Flynn, Nathan E.
    Liu, Lunxu
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (03)